Thus, the combination of neuroblastoma weakly basic chemotherapeutics with selective HDAC10 inhibitors or HDAC inhibitors targeting HDAC10 in their inhibitory profile, might be beneficial for the treatment of high-risk, treatment-resistant neuroblastomas with low off-target effects on non-transformed cells. The gene discussed is HDAC10; the disease is neuroblastoma.